Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP/microtubule affinity-regulating kinase 2 (MARK2), also known as Par-1b, is a serine/threonine protein kinase belonging to the AMP-activated protein kinase (AMPK) family. It plays a fundamental role in establishing and maintaining cell polarity in epithelial and neuronal cells, as well as regulating microtubule dynamics by phosphorylating microtubule-associated proteins (MAPs) such as tau, MAP2, and MAP4. Phosphorylation of these proteins by MARK2 causes them to detach from microtubules, leading to microtubule destabilization and cytoskeletal remodeling. Additionally, MARK2 acts as a critical stress-sensing cytosolic regulator that phosphorylates eIF2alpha under proteotoxic stress, thereby modulating protein translation.\n\nIn disease states, MARK2 is heavily implicated in neurodegenerative disorders and oncology. In Alzheimer's disease, MARK2-mediated hyperphosphorylation of tau at Ser262 promotes the formation of neurofibrillary tangles and neurotoxicity. In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), MARK2-eIF2alpha signaling is activated by misfolded proteins, promoting repeat-associated non-AUG (RAN) translation of toxic dipeptide repeats. In oncology, MARK2 is overexpressed in various malignancies, including pancreatic, ovarian, and breast cancers, where it supports tumor growth, metastasis, and chemoresistance (e.g., to paclitaxel and cisplatin) by regulating the Hippo/YAP pathway and class IIa HDACs. Pharmacological targeting of MARK2 is an active area of research, with small-molecule inhibitors like MRT199665, MARK-IN-2, and the tool compound 39621 being used to study its biology. Furthermore, the approved ALK inhibitor brigatinib has been identified as a potent off-target inhibitor of MARK2/3, offering potential drug repurposing opportunities for YAP/TAZ-dependent cancers.
ATP-competitive inhibition of the kinase domain to block phosphorylation of downstream substrates such as tau, MAPs, and eIF2alpha.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAP/microtubule affinity-regulating kinase 2 (MARK2).